8-K: Senseonics Highlights Eversense CGM Growth and Future Pipeline at Stifel Healthcare Conference

Senseonics presented at the Stifel 2024 Healthcare Conference, showcasing the commercial launch of Eversense 365 and outlining future product development.

Summary

• Senseonics presented at the Stifel 2024 Healthcare Conference, providing an update on their Eversense CGM system.
• The company highlighted the recent FDA clearance and commercial launch of the Eversense 365, a long-term implantable continuous glucose monitor.
• The presentation emphasized the unique features of Eversense, including its one-year sensor life, implantable design, and accuracy.
• Senseonics is targeting a large market, with the U.S. CGM market estimated to be over $20 billion.
• The company has a distribution agreement with Ascensia Diabetes Care and a collaboration with Mercy Health, which could potentially benefit 30,000 patients.
• Senseonics is also developing next-generation devices, including the Gemini and Freedom systems, with IDE filings planned for 2025.
• The company projects that less than 1% market share of current CGM patients is needed for profitability.
• The Eversense 365 system has shown strong early indicators, with a 2.3x increase in direct-to-consumer leads compared to the Eversense 180.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong early launch indicators, innovative product development, and strategic partnerships. The company is addressing a large market with a differentiated product. However, there are inherent risks in the development and commercialization of new technologies.

Positives

• Eversense 365 is the first and only fully implantable CGM that lasts for one year.
• The system has a Mean Absolute Relative Difference (MARD) of 8.7%, indicating high accuracy.
• The company has secured a global distribution agreement with Ascensia Diabetes Care.
• The collaboration with Mercy Health has the potential to reach 30,000 patients.
• The company is developing innovative next-generation devices, Gemini and Freedom.
• Reimbursement access is expanding, covering over 300 million lives.
• Early launch indicators for Eversense 365 are strong, with a 2.3x increase in direct-to-consumer leads.
• The company projects that less than 1% market share of current CGM patients is needed for profitability.

Negatives

• The company is reliant on Ascensia for commercialization efforts.
• The development of new technologies and regulatory approvals are subject to uncertainties.
• The company faces competition from other CGM manufacturers.
• The market penetration of CGMs is still relatively low, with only about 25% of eligible patients using them.

Risks

• The commercial launch and expansion of the Eversense product and RPM solution are subject to uncertainties.
• The company relies on Ascensia's commercialization efforts and investments.
• There are uncertainties in finalizing integration and commercial terms with partners.
• User decisions and responses to new technology are uncertain.
• Regulatory and administrative processes and decisions can impact the company.
• The development and registration of new technology are subject to uncertainties.
• The current economic environment poses risks.
• The development of the overall CGM market is uncertain.
• The Gemini and Freedom development programs are subject to change based on various factors.

Future Outlook

Senseonics anticipates continued growth in the CGM market and plans to expand its product offerings with the Gemini and Freedom systems. The company expects to achieve profitability with less than 1% market share of current CGM patients. They also plan to expand their partnerships and collaborations to increase market penetration.

Management Comments

• Senseonics aims to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.
• Management believes the Eversense CGM system addresses unmet needs in the market.
• The company is focused on streamlined operations in manufacturing, research, and development of next-generation Eversense systems.

Industry Context

The announcement aligns with the broader trend of increasing adoption of continuous glucose monitoring technology in diabetes management. The company is positioning itself as a leader in long-term implantable CGM solutions, differentiating itself from competitors offering shorter-term devices. The partnership with Ascensia leverages their existing global reach in diabetes care.

Comparison to Industry Standards

• The Eversense 365 system's 1-year sensor life is a significant differentiator compared to competitors like Dexcom and Abbott, whose sensors typically last 10-14 days.
• The Mean Absolute Relative Difference (MARD) of 8.7% for Eversense 365 is competitive with other leading CGM systems.
• The implantable nature of the Eversense sensor is unique compared to the wearable sensors of competitors.
• The collaboration with Mercy Health is a strategic move to gain access to a large patient population, similar to how other CGM companies partner with healthcare providers.
• The development of the Gemini and Freedom systems indicates a focus on innovation, similar to how Dexcom and Abbott are continuously improving their technology.

Stakeholder Impact

• Shareholders may benefit from the potential growth and profitability of the company.
• Patients will have access to a long-term, accurate, and convenient CGM solution.
• Healthcare providers will have a new tool for managing diabetes patients.
• Ascensia Diabetes Care will benefit from the distribution agreement.
• Mercy Health will benefit from the collaboration and improved patient outcomes.

Next Steps

• Senseonics plans to continue the commercial launch of Eversense 365.
• The company will focus on building brand awareness and adoption.
• They will protect and grow the installed base of Eversense users.
• Senseonics will continue to develop the Gemini and Freedom systems.
• The company plans to submit an IDE for the Gemini system in 2025.
• They will expand collaborations with health systems, building on the Mercy Health partnership.

Key Dates

Keywords

Continuous Glucose Monitoring, CGM, Eversense, Diabetes, Implantable Sensor, Ascensia Diabetes Care, Mercy Health, Gemini System, Freedom System, FDA Clearance